

N. Ireland Cancer Registry Implications of Research for Services

NICR Lead Author <i>(Office use only)</i>
Paper ID <i>(Office use only)</i>
Date Submitted to NICR Steering Group Click here to enter a date. <i>(Office use only)</i>

Paper Title	Time intervals and routes to diagnosis for lung cancer in 10 jurisdictions: cross-sectional study findings from the International Cancer Benchmarking Partnership (ICBP)
Authors	Usha Menon, Peter Vedsted, Alina Zalounina Falborg, Henry Jensen, Samantha Harrison, Irene Reguilon, Andriana Barisic, Rebecca J Bergin, David H Brewster, John Butler, Odd Terje Brustugun, Oliver Bucher, Victoria Cairnduff, Anna Gavin, Eva Grunfeld, Elizabeth Harland, Jatinderpal Kalsi, Anne Kari Knudsen, Mats Lambe, Rebecca-Jane Law, Yulan Lin, Martin Malmberg, Donna Turner, Richard D Neal, Victoria White, David Weller
Journal	BMJ Open
DOI	10.1136/bmjopen2018-025895
Funders	CancerCare Manitoba; Cancer Care Ontario; Canadian Partnership Against Cancer; Cancer Council Victoria; Cancer Research Wales; Cancer Research UK; Danish Cancer Society; Danish Health and Medicines Authority; European Palliative Care Research Centre; Norwegian University of Science and Technology; Northern Ireland Guidelines Audit and Implementation Network; Macmillan Cancer Support; National Cancer Action Team; National Health Service (NHS) England; Medical Research Council, Northern Ireland Cancer Registry, funded by the Public Health Agency Northern Ireland; Norwegian Directorate of Health; Research Centre for Cancer Diagnosis in Primary Care, Aarhus University, Denmark; Scottish Government; Swedish Association of Local Authorities and Regions; University College London and NIHR Biomedical Research Centre at University College London NHS Foundation Trust; University of Edinburgh; Victorian Department of Health and Human Services; and Welsh Government.
Full paper available online	YES <input checked="" type="checkbox"/> NO <input type="checkbox"/> NOT YET <input type="checkbox"/>
Conclusion	There are differences between jurisdictions in interval to treatment, which are magnified in patients with lung cancer who wait the longest.

What this means for the service	The data could help jurisdictions develop more focused lung cancer policy and targeted clinical initiatives